The use of ultra-rapid lispro insulin proven to reduce postprandial hyperglycemia faster than human insulin
Controlling diabetes can be very challenging but with the advent of Ultra-Rapid Lispro Insulin which is extremely fast-acting mealtime insulin, it has become easy to treat diabetes. This insulin is made by Eli Lily Pharmaceuticals and manufactured by Sanofi Aventis. It has very low toxicity to the kidney and liver. This insulin delivery system contains the same biological activity as regular human insulin, which is why the product is referred to as an even more effective way to control blood glucose levels than normal human insulin. The ultra-rapid lispro also has been found to stimulate more natural hormone production in the body by stimulating pancreatic and pituitary secretions which increases the amount of insulin the pancreas can produce. Moreover, ultra rapid lispro insulin is based on the patented ultra-rapid insulin technology developed by Eli Lily Pharmaceuticals and Sanofi Aventis, which was first used in the treatment of hypoglycemia in the 1990s. The ultra-rapid lispro ins...